PharmaVoice
AUGUST 10, 2022
Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.
PhRMA
AUGUST 10, 2022
Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to stand up for patients and medical innovation by opposing the bill.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmExec
AUGUST 10, 2022
The technology is not just about digital enablement anymore.
PhRMA
AUGUST 10, 2022
We need to move toward a more value-driven health care system that centers around patients’ needs. Sound evidence can help guide us toward that, and we’re committed to developing tools to help patients, physicians and others make informed decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmExec
AUGUST 10, 2022
Failed efforts do not overshadow field’s progress, resolve.
PharmaVoice
AUGUST 10, 2022
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PharmExec
AUGUST 10, 2022
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
Pharmacy Times
AUGUST 10, 2022
Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.
Pharmaceutical Technology
AUGUST 10, 2022
The US Food and Drug Administration (FDA) has granted Fast-Track designation to Relmada Therapeutics’ REL-1017 as a single agent to treat major depressive disorder (MDD). A new chemical entity and NMDA receptor (NMDAR) channel blocker, REL-1017 acts on hyperactive channels while preserving physiological glutamatergic neurotransmission. Presently, the therapy is being analysed in late-stage studies.
Pharmacy Times
AUGUST 10, 2022
Investigators from NYU’s Grossman School of Medicine sound alarm on treatment gap and suggest ways to remove barriers, as opioid overdoses soar to historic levels.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmExec
AUGUST 10, 2022
Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways.
Pharmacy Times
AUGUST 10, 2022
Pharmacists can play an important role in helping ensure compliance with prescribed medications, which can help seniors maintain their health and quality of life while aging at home.
The Guardian - Pharmaceutical Industry
AUGUST 10, 2022
The pharmacy chain failed to properly investigate suspicious opioid orders, according to federal ruling Walgreens “substantially contributed” to San Francisco’s opioid epidemic by failing to perform due diligence on prescriptions that flooded into the city for 15 years, a federal judge has found. The city won what local media has called a “ landmark trial ” against Walgreens, with the judge, Charles Breyer, finding that the pharmacy chain had failed to properly investigate suspicious opioid orde
Pharmacy Times
AUGUST 10, 2022
Meta-analysis of randomized controlled trials adds to growing evidence around certain antihypertensive drug classes showing promise for primary or secondary prevention of diabetes.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
AUGUST 10, 2022
A study published in Nature Medicine demonstrates that active brain metastases in breast cancer patients are partially or even completely regressed by an antibody-drug conjugate (ADC), trastzumab deruxtecan (T-Dxd). The researchers stated that the results are considered ground-breaking in the treatment of brain metastases – and that ADCs open up “a completely new avenue in oncological research and targeted therapy”.
Pharmacy Times
AUGUST 10, 2022
A new study predicts significant increases in cardiovascular issues in the United States, highlighting racial and ethnic inequality of future patients.
European Pharmaceutical Review
AUGUST 10, 2022
In order to meet microbiological quality standards, herbal medicine pills are often irradiated at the primary package or final product stage. Radiation is chosen over thermal terminal sterilisation to minimise decomposition of crude drug components, volatilisation of essential oils and changes in colour. However, with limited evidence on the impact ionising radiation has on the constituents of such products, researchers set out to investigate whether irradiation impacts drug quality beyond micro
Pharmaceutical Commerce
AUGUST 10, 2022
Recognizing the sustainability issue is an important step, but the biopharmaceutical sector encompasses a complex set of networks and supply chains, so it is not straightforward to shift towards net zero across all operations.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
DiversifyRx
AUGUST 10, 2022
Independent pharmacies can play a significant role in helping local communities prepare for back to school. As most parents know, schools are a petri dish for all things contagious. From preschool to high school, students’ and teachers’ immune systems are tested each return of the school year. As a local independent pharmacy owner, you can help prevent and treat common ailments arising from back to school activities.
European Pharmaceutical Review
AUGUST 10, 2022
Amgen has entered into a definitive agreement to acquire ChemoCentryx Inc., a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Under the agreement, ChemoCentryx will be acquired for $52 per share in cash, for a total enterprise value of approximately $3.7 billion. “The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephro
Pharmaceutical Technology
AUGUST 10, 2022
Cerevance has entered a multi-year strategic research partnership with Merck (MSD outside North America) to discover new targets for Alzheimer’s disease. Under the alliance, the companies will use the Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform of Cerevance to identify the targets. Furthermore, Cerevance will simultaneously out-license a discovery-stage programme to Merck under the partnership.
Pharmacy Times
AUGUST 10, 2022
Health care professionals need to work closely with patients in understanding polypharmacy and the risk/benefit of pharmacotherapy.
PharmExec
AUGUST 10, 2022
How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.
Pharmacy Times
AUGUST 10, 2022
Cangrelor (Kengreal) is indicated as an adjunct to percutaneous coronary intervention for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis.
PharmExec
AUGUST 10, 2022
Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.
Pharmacy Times
AUGUST 10, 2022
Heidi D. Finnes, PharmD, BCOP, FHOPA, president-elect of Hematology/Oncology Pharmacy Association (HOPA), explains how HOPA can help prepare PGY2 pharmacy residents to obtain and maintain their BCOP certification.
Pharmaceutical Technology
AUGUST 10, 2022
Catale n t has signed an agreement for the acquisition of full-service specialty Contract Development and Manufacturing Organization (CDMO) Metrics Contract Services for $475m from Mayne Pharma. The takeover of Metrics will bolster the expertise of Catalent in the development of integrated oral solid formulation, production and packaging to aid customers in streamlining and expediting their programmes.
Pharmacy Times
AUGUST 10, 2022
Part 3 in a series outlining 5 crucial steps pharmacies can take to enhance patient engagement and lower operational costs.
The Social Pharmacist
AUGUST 10, 2022
Campaigns dedicated to Christmas marketing in social media are a fantastic opportunity for eCommerce markets to go all-out on their channels. Apart from merely jumping on the bandwagon by pushing out normal festive greetings, you need the best strategy with your creative posts. Furthermore, many businesses also take the opportunity to showcase holiday spirit, increase their customer engagement to new and old customers and spread the holiday spirit around!
PQA
AUGUST 10, 2022
PQA follows a systematic, transparent and consensus-based development?process?to ensure that measures are important, scientifically acceptable, feasible and usable. However, the measurement lifecycle does not end when a measure is endorsed. Previous blogs have?walked through?the?measure conceptualization,?measure specification and measure?testing and measure endorsement phases?
The FDA Law Blog
AUGUST 10, 2022
By Sara W. Koblitz — For years , FDA has been wrestling with questions about what patents should be listed in the Orange Book, but, as we have reported, FDA has made little to no progress on addressing those questions. One of those pressing questions that remains unanswered involves the listing of REMS patents in the Orange Book. While FDA asked for Comments in 2020 about whether REMS patents, among others, “are in fact the type of patents that must be submitted” for listing in the Orange Book
PharmExec
AUGUST 10, 2022
Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.
Pharmaceutical Technology
AUGUST 10, 2022
North America extended its dominance for artificial intelligence (AI) hiring among pharmaceutical industry companies in the three months ending June. The number of roles in North America made up 53.2% of total AI jobs - up from 47.6% in the same quarter last year. That was followed by Asia-Pacific, which saw a 0.9 year-on-year percentage point change in AI roles.
Expert insights. Personalized for you.
290 
Let's personalize your content